Short time horizons for fracture prediction tools: time for a rethink.

Accepted/In Press date: 13 April 2021

Published date: June 2021

Additional Information: Funding Information: JAK, NCH, ML and EVM are responsible for the creation and maintenance of FRAX but derive no financial benefit. EVM has received consultancy/lecture fees/grant funding/honoraria from AgNovos, Amgen, AstraZeneca, Consilient Healthcare, Fresenius Kabi, Gilead, GSK, Hologic, Internis, Lilly, Merck, Novartis, Pfizer, Radius Health, Redx Oncology, Roche, Sanofi Aventis, UCB, ViiV, Warner Chilcott and I3 Innovus. FB is employed by and is a shareholder of Quantify Research, a health economic research consultancy. CC reports personal fees from Alliance for Better Bone Health, Amgen, Eli Lilly, GSK, Medtronic, Merck, Novartis, Pfizer, Roche, Servier, Takeda and UCB. NCH has received consultancy/lecture fees/honoraria/grant funding from Alliance for Better Bone Health, Amgen, MSD, Eli Lilly, Radius Health, Servier, Shire, UCB, Consilient Healthcare and Internis Pharma. MKJ declares no conflicts of interest. ML has received lecture fees from Amgen, Lilly, Meda, Renapharma and UCB Pharma and consulting fees from Amgen, Radius Health, UCB Pharma, Renapharma and Consilient Health, all outside the presented work. JAK reports no additional competing interests. Copyright: Copyright 2021 Elsevier B.V., All rights reserved.

Local EPrints ID: 448972

URI: http://eprints.soton.ac.uk/id/eprint/448972

DOI: doi:10.1007/s00198-021-05962-y

ISSN: 0937-941X

PURE UUID: f751edc0-a7cc-440e-988e-6adb02b6ed2e

ORCID for Cyrus Cooper: orcid.org/0000-0003-3510-0709

ORCID for Nicholas C. Harvey: orcid.org/0000-0002-8194-2512

Date deposited: 12 May 2021 16:31

Last modified: 18 Mar 2024 05:05